On Feb. 25, 2020, Vir Biotech announced a development and manufacturing collaboration to advance and produce human monoclonal antibodies for the potential treatment of COVID-19 (Coronavirus Disease 2019), a disease caused by SARS-CoV-2.

WuXi Biologics conducted cell-line development, process and formulation development, and initial manufacturing for clinical development. If the antibodies received regulatory approvals, WuXi Biologics had the rights to commercialize therapies in Greater China, and Vir had the rights to commercialize therapies in all other markets worldwide.